Tecentriq (Atezolizumab) vs Retsevmo (selpercatinib)
Tecentriq (Atezolizumab) vs Retsevmo (selpercatinib)
Tecentriq (atezolizumab) is an immune checkpoint inhibitor designed to target and block the PD-L1 protein on tumor cells, thereby enhancing the body's immune response against cancer cells, and it's commonly used in the treatment of various types of cancers including non-small cell lung cancer, small cell lung cancer, and urothelial carcinoma. Retsevmo (selpercatinib), on the other hand, is a selective RET kinase inhibitor indicated for the treatment of certain types of thyroid cancers and non-small cell lung cancer that have a RET gene alteration, which is a specific genetic mutation that drives tumor growth. When deciding between Tecentriq and Retsevmo, it is crucial to consider the specific type and genetic profile of the cancer, as well as the patient's overall health and treatment goals, since each medication targets different pathways and mechanisms in the treatment of cancer.
Difference between Tecentriq and Retsevmo
| Metric | Tecentriq (Atezolizumab) | Retsevmo (selpercatinib) |
|---|---|---|
| Generic name | Atezolizumab | Selpercatinib |
| Indications | Urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer | RET-altered thyroid cancers, non-small cell lung cancer |
| Mechanism of action | PD-L1 inhibitor, immune checkpoint inhibitor | RET kinase inhibitor |
| Brand names | Tecentriq | Retsevmo |
| Administrative route | IV infusion | Oral |
| Side effects | Fatigue, nausea, decreased appetite, urinary tract infection, fever | Increased liver enzymes, hypertension, fatigue, edema, diarrhea |
| Contraindications | None known beyond hypersensitivity to atezolizumab or its excipients | None known beyond hypersensitivity to selpercatinib or its excipients |
| Drug class | Monoclonal antibody, Immune checkpoint inhibitor | Kinase inhibitor |
| Manufacturer | Genentech (Roche) | Eli Lilly and Company |
Efficacy
Efficacy of Tecentriq (Atezolizumab) in Lung Cancer Treatment
Tecentriq (Atezolizumab) is an immune checkpoint inhibitor specifically designed to target and bind to the programmed death-ligand 1 (PD-L1) protein, which is found on the surface of cells. By blocking PD-L1, Tecentriq enables the activation of T-cells, which can then recognize and attack cancer cells. In the context of non-small cell lung cancer (NSCLC), Tecentriq has shown efficacy both as a monotherapy and in combination with other cancer treatments. Clinical trials have demonstrated improved survival rates in patients with high PD-L1 expression when treated with Tecentriq, compared to those who received chemotherapy alone.
For patients with small cell lung cancer (SCLC), Tecentriq has also shown a significant impact when used in combination with chemotherapy. Studies have indicated that the addition of Tecentriq to the standard chemotherapy regimen can lead to a longer duration of response and an improvement in overall survival. The efficacy of Tecentriq in lung cancer highlights the importance of immunotherapy as a treatment modality and provides a valuable option for patients with PD-L1-positive lung cancer.
Efficacy of Retsevmo (Selpercatinib) in Lung Cancer Treatment
Retsevmo (Selpercatinib) is a targeted therapy that has been developed to treat lung cancers with specific genetic alterations. It is a selective RET kinase inhibitor, designed to block the activity of the RET protein, which can drive cancer growth in some individuals. Retsevmo has shown significant efficacy in treating non-small cell lung cancer (NSCLC) with RET gene fusions, a subgroup of lung cancer patients who historically have had limited treatment options.
Clinical trials have demonstrated that Retsevmo can lead to high response rates and prolonged progression-free survival in NSCLC patients with RET fusion-positive tumors. The drug has been particularly effective for patients who have not responded to prior therapies, including chemotherapy and other targeted treatments. The efficacy of Retsevmo in this patient population provides a promising new avenue for personalized medicine in lung cancer, where treatment can be tailored to the genetic profile of the tumor.
Regulatory Agency Approvals
Tecentriq
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Retsevmo
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Tecentriq or Retsevmo today
If Tecentriq or Retsevmo are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us